Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...

Ouro Medicines, a new biotechnology startup, launched Friday with $120 million in funding to develop antibody drugs for ...

Ouro’s series A was co-led by TPG Life Sciences Innovations, NEA and Norwest Venture Partners. Monograph Capital participated in the round and also founded the company in partnership with GSK ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of adult patients with primary advanced or recurrent ...

Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx w ...